CSL has announced the appointment of Dr Paul McKenzie as its new chief operating officer.
“Paul has a demonstrated track record of success in leading operational excellence and he brings significant leadership capabilities that will continue to drive CSL’s sustainable growth,” said CSL CEO and managing director, Paul Perreault.
“Throughout his 30- year career, Paul has earned a reputation as a patient-focused business leader - an important attribute as we continue to invest in our science, facilities and commercial capabilities for delivering better outcomes to patients and protecting public health. I look forward to working with Paul and the rest of our leadership team in executing our strategy and continuing to sustainably grow our global business.”
Dr McKenzie has served in a range of operational leadership roles in the biopharma and biotech industries since 1992.
Most recently, he was executive vice president of pharmaceutical operations and technology at Biogen where he was responsible for asset management, technical development, global manufacturing, supply chain operations, CMC regulatory, quality and engineering.
Dr McKenzie has also held leadership roles in research and development, science and technology and operations with Johnson & Johnson, Bristol-Myers Squibb and MSD.
CSL said he will be responsible for leading the newly formed global end-to-end supply chain organisation and its accompanying strategy. This includes manufacturing, manufacturing technical support, CSL Plasma, quality, engineering, environment, health and safety (EHS), business technology, planning, logistics, sourcing, business services and enterprise excellence.
“Now is an incredibly exciting time to be a part of CSL. I am thrilled to join a growing global biotech leader and a well-established management team that is keenly focused on creating value for shareholders, patients, employees and the communities in which it operates,” said Dr McKenzie.
“I look forward to contributing to CSL’s future growth and success in delivering on the promise of innovative medicines to treat patients and protect public health around the world.”
Dr McKenzie's appointments is effective 3 June 2019.